Program. Basal Insulin in the Modern Era The CDE's Role in Improving Utilization and Outcomes.

Slides:

Advertisements

Similar presentations

Consider this Combo: GLP-1 Receptor Agonists and Basal Insulin Matt Heinsen, PharmD PGY2 Pharmacotherapy Resident Butler University & Community Health.

Advertisements

What's New in Basal Insulin for Diabetes

Recommendation In people with clinical cardiovascular disease in whom glycemic targets are not met, a SGLT2 inhibitor with demonstrated cardiovascular.

Type 1 Diabetes: Meters, Pumps, and Transitions to Adulthood

Short-, Intermediate-, Long-Acting Insulins

Engaging the INSULIN-TREATED T2DM Patient: the Importance of Real-World Data.

Applying Data to Practice

Special Consideration in Insulin Therapy

Using the AGP to Standardize Glucose Reporting

SGLT2 Inhibitors: What Do the Data Mean for My Patients?

New Patient-Friendly Options for Managing Insulin Dosing

The Next Generation of Basal Insulins

Modern Strategies for Basal Insulin Use in T2D

Patient Case Discussions in T2D: What Intensification Plan Is Best?

Moderate-Intensity Statins for Dyslipidemia: How to Treat Today?

Insulin Innovation.

Program Goals. Consulting the Experts: Prandial Insulin or a GLP-1 Receptor Agonist as Add-On to Basal Insulin.

Insulin Intensification Strategies in Later-Stage Type 2 Diabetes Mellitus.

How Early Should Basal Insulin Be Used in T2D Management?

Novel Concentrated Insulins: What Benefits and for Which Patients?

Antihyperglycemic therapy in type 2 diabetes: general recommendations.

SGLT2 Inhibitors in the Modern Era: Why and Where?

Working as a Team for Improved Patient Outcomes in Type 2 Diabetes

Examining CV Effects of Basal Insulin Therapy

What Do Primary Care Physicians Need to Know About Insulin/GLP-1 RA Fixed-Ratio Combinations?

Innovative Insulin Combinations: A New strategy for the Person With T2DM.

nAMD: Switching Therapies - what you need to know

Goals. Achieving HbA1c Goals: Applying Guidelines to Intensify Therapy in Patients With Diabetes.

Emerging CVOT Data and Clinical Application

How Effective Is Fixed-Dose Combination Therapy in T2D and Where Does It Fit?

Program Goals. What Will the Emerging Basal Insulin Products Mean for My Diabetes Practice?

Emerging Basal Insulins for Diabetes

GLP-1 Receptor Agonists: How Early Is Appropriate?

Talking to Patients About Diabetes Management

PCP View: ACC/AHA Guidelines: Role of Moderate Intensity Statins

Novel Insulin Combinations: What Does the Primary Care Physician Need to Know?

Integrated Diabetes Care: How Can We Make the Best Use of New Technology?

A Journal Club on Lipid Management:

Early and Intensive T2D Management:

Novel Basal Insulin Formulations in the Modern Era of T2D Management

Insulin Use in Primary Care: Practice Challenges

Statins and HIV:.

Insulin Innovation.

Injectable Options as Add-Ons to Basal Insulin: Targeting PPG in Type 2 Diabetes Patients.

New Horizons in Adjunctive Type 1 Diabetes Management With SGLT Inhibitors.

Simplifying Insulin Delivery for Better Patient Outcomes in T2D

Novel Approaches to T1D Management

Antihyperglycemic therapy in type 2 diabetes: general recommendations.

Combining Efforts for Older Drivers: Licensing Agencies, Occupational Therapists, and Clinicians.

Better Diabetes Control With Novel Basal Insulins

Novel Insulin/GLP-1 Combinations: Of Interest to the Primary Care Physician?

Optimizing Insulin Therapy in Primary Care: Basal Plus Incretin Combinations.

Younger Patients With Type 1 Diabetes: Can We Optimize Their Insulin Therapy?

Dual SGLT1/SGLT2 Inhibition in T1D

Frequency of potential risk of hypoglycemia for each estimate method, defined as a percentage difference between the estimate and final basal rate. Frequency.

Current Challenges in Managing Hemophilia

Insulin in Diabetes Management: Effective Patient Selection Is Key

COMBINATIONS AND COFORMULATIONS: THE FUTURE OF INSULIN THERAPY?

Liraglutide Shows CV Benefit: Clinical Perspectives on the LEADER Trial

Patient Selection for Modern T2D Agents

Hypoglycemia Is BAD.

Improving Effective Basal Insulin Use in Clinical Practice

Are All Novel Insulins Proven to Be Equally Safe?

Emerging Combination Injectable Therapy A New Era in Diabetes Care

What's New in Oral Combination Therapy for Type 2 Diabetes?

Practical Strategies for Overcoming Emotional Barriers to Insulin Initiation in the Primary Care Setting.

Fixed-Ratio Combination Therapy in T2DM

Emerging Basal Insulins for Diabetes

Fresh perspectives ON BASAL Insulins in diabetes care

The Challenge of Insulin Titration

Presentation transcript:

Basal Insulin in the Modern Era The CDE's Role in Improving Utilization and Outcomes

Program

Basal Insulin 101

Antihyperglycemic Therapy in Adults With T2D

Antihyperglycemic Therapy in Adults With T2D (cont)

Drug-Specific and Individual Factors to Consider

Pharmacokinetic Profile of Currently Available Single Insulin Products

Ultra-Long-Acting Insulins Potential Benefits in T2D

Basal Insulin Initiation in People With T2D

U-300 Insulin Glargine Determining Starting Dose (and Dose Conversion) in T2D

Insulin Glargine U-100 vs U-300 in People With T2D Meta-Analysis of 3 Phase 3 Studies

Flexible vs Fixed Dosing U-300 Glargine Sub-Studies of Phase 3 Studies

Insulin Degludec Determining Starting Dose (and Dose Conversion) in T2D

Insulin Degludec Hypoglycemia

Flexible vs Fixed Dosing of Insulin Degludec

Ultra-Long-Acting Insulin Comparison

Who May Benefit From Ultra-Long-Acting Insulins?

Reasons for Switching Insulin Products

Overcoming Insulin-Related Barriers Like a Pro

Barriers to Insulin Initiation Persons Living With Diabetes

Barriers to Insulin Initiation Clinicians

Strategies to Overcome Barriers Persons Living With Diabetes

Education in Insulin Initiation Insulin Delivery

Overcoming Barriers in Clinicians

Overcoming Barriers With Education Collaborative Model of Care

Case Challenges!

Challenge for Diabetes Educators Balancing the Art and Science of DSMES

The Diabetes Educator's Role in Improving Insulin Utilization and Outcomes

Case Vignette: Part 1

Faculty Discussion

Faculty Discussion (cont)

Faculty Discussion (cont)

Case Vignette: Part 2

Faculty Discussion

Case Vignette: Part 3

Faculty Discussion

Abbreviations

Abbreviations (cont)